TABLE 2.
Patient characteristics of the patients in the risperidone/paliperidone subgroup
| Trait | Total sample | Men | Women |
|---|---|---|---|
| n | 76 | 31 (40.8%) | 45 (59.2%) |
| Age (y) | |||
| Mean ± SD | 38.1 ± 14.1 | 33.1 ± 11.5 | 41.6 ± 14.8 |
| Median | 34 | 31 | 40 |
| Daily dose in CPZeq | |||
| Median | 300 | 396 | 200 |
| Duration of disease (y) | |||
| Mean ± SD | 12.5 ± 12.3 | 9.6 ± 10.0 | 14.5 ± 13.4 |
| Median | 10.0 | 6.5 | 11.0 |
| Type of therapy | |||
| Atypical antipsychotics | 66 (86.8%) | 25 (80.6%) | 41 (91.1%) |
| Combination therapy | 10 (13.2%) | 6 (19.4%) | 4 (8.9%) |
| Smoking (+/−/?) | 31 (40.8%) /43 (56.6%) /2 (2.6%) | 21 (67.7%) /10 (32.3%) /0 | 10 (22.2%) /33 (73.3%) /2 (4.5%) |
| Hyperprolactinaemia (+/−) | 59 (77.6%)/17(22.4%) | 20 (64.5%)/11 (35.5%) | 39 (86.6%) /6 (13.3%) |
| Prolactin (ng/mL) total | |||
| Mean ± SD | 53.0 ± 34.4 | 35.8 ± 29.3 | 64.9 ± 32.9 |
| Range | 4.6–124.0 | 4.6–122.1 | 6.4–124.0 |
| Prolactin (ng/mL; HPRL+) | |||
| Mean ± SD | 64.9 ± 29.7 | 49.2 ± 28.5 | 72.9 ± 27.4 |
| Range | 20.2–124.0 | 20.2–122.1 | 28.1–124.0 |
| Prolactin (ng/mL; HPRL–) | |||
| Mean ± SD | 11.9 ± 4.8 | 11.6 ± 5.6 | 12.5 ± 3.5 |
| Range | 4.6–19.1 | 4.6–19.1 | 6.3–16.5 |
CPZeq, chlorpromazine equivalents; HPRL, hyperprolactinaemia.